DYN

Announcements

Nothing here yet

Daily updates

• Dyne planned to present additional ACHIEVE data for z-basivarsen in DM1Sep 14, 2026
• Dyne prepared one-year ACHIEVE data for z-basivarsen in myotonic dystrophy type 1Sep 8, 2026

FDA designations

• Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD)Aug 4, 2025

News

• Dyne Therapeutics reports additional one-year clinical data from the Phase 1/2 ACHIEVE trial of Z-Basivarsen (DYNE-101) in myotonic dystrophy type 1Sep 30, 2026
• Dyne Therapeutics will present additional one-year Phase 1/2 ACHIEVE data for DYNE-101 in myotonic dystrophy type 1 at upcoming medical meetingsSep 8, 2026
• Dyne Therapeutics receives FDA IND clearance for DYNE-302 in facioscapulohumeral muscular dystrophyJul 28, 2026
• Dyne Therapeutics receives FDA acceptance of its biologics license application for Z-Rostudirsen in Exon 51 Duchenne muscular dystrophyJul 21, 2026
• Dyne Therapeutics completed enrollment in the registrational expansion cohort of the ACHIEVE trial for Z-BasivarsenJun 3, 2026